1 Francesca Laylah Jamilah 108 iryou/iryou/topics/tp html Fran
|
|
|
- しまな えいさか
- 9 years ago
- Views:
Transcription
1 108 Francesca Laylah Jamilah A B C D E F G H I A B C D E F G H I
2 1 Francesca Laylah Jamilah iryou/iryou/topics/tp html Francesca Laylah Jamilah 2 fibre 2
3 3 3.1 A 1. (a., b. ) (a., b., c. ) 1) 2. Kaposi ( ) ( ) 2) Steavens-Johnson 3. 3) (a., b. ) (a., b. ) 4. 4) ( ) 5) (a. B, b. T ) % 6) (a., b. ) (a., b. ) 5. ( ) 7) 0 0-I 0-III 0-I 0-III 0-I ( ) ( ) (a., b., c. ) 0-III ( ) 0-II 0-II 0-IIa 0-IIc 0-IIa 0-I ( ) 0-IIc 0-III ( ) 0-IIb 0-II 8) 6. Candida albicans Candida (a., b., c. ),, 1) (a., b., c. ) 9) ( ) 9) 3
4 ( ) ( ) 1) 9) ( 108 ) 7. ( ) ( ) Cushing ( ) 7) Cushing ( ) (a., b. ) (a., b. ) (a., b. ) (a., b. ) ( ) Na +, Cl 7) ( ) 10) 8. (a., b., c. ) ( ) (a., b., c. ) 20 11) ( ) ( ) 9. ( ) ( ) ( ) (a., b., c. ) 10. ( ) ( ) (a., b. ) (a., b. ) (a., b. ) (a., b. ) 11. ( ) ( ) ( ) ( ) ( ) 12. (a., b. ) 3 (a., b. ) Stanford ( ) A ( ) B De Bakey I (a., b. ) (a., b. ) II ( ) III ( ) 8) 4
5 13. (a., b. ) T2 ( ) ( ) ( ) ( ) 9) ( ) ( ) ( ) ( ) (a., b. ) ( 108 ) 14. ( ) (a., b., c. ) 13) ( ) (a., b. ) 15. (a., b., c. ) (a., b., c. ) 16. ( ) ( ) ( ) 5) (a., b., c. ) (a., b. ) (a., b. ) 5) (a., b. ) (a., b. ) 6) 17. ( ) ( ) 5) (a., b., c. ), (a., b., c. ), (a., b., c., d. ), (a., b., c. ) (a., b. ) 30 (a., b. ) 14) ( ) (a., b. ) 7) ( ) (a., b. ) 7) ( ) (a., b. ) (a., b. ) (a., b. ) (a., b. ) (a., b. 5
6 ) 5) (a., b. ) 18. (Graft-versus-host disease; GVHD) ( ) GVHD GVHD GVHD (a., b., c. ) GVHD ( ) ( ), ( ), ( ) GVHD ( ) (a., b. ) GVHD (a., b., c. ) ( ) 2) 19. ( ) ( ) (a., b., c. ) ( ) ( ) ( ) 1-3 % ( ) 10 % ( ) -O- ( ) ( ) 10) 20. ( ) (a., b. ) (a., b. ) ( ) Na + (a., b. ) (a., b. ) 14) Sheehan ( ) ( ) ( ) (a., b. ) 21. ( ) (a., b., c. ) 1 (a., b., c. ) ( ) (a., b. ) ( ) (a., b. ) (a., b. ) (a., b., c. ) (a., b. ) 6
7 (a., b. ) ( ) 15) 22. ( ) ( ) ( ) ( ) ( ) (a., b., c. ) ( ) ( ) ( ) 16) 23. ( ) ( ) ( ), ( ) ( 108 MR ) 24. ( ) I ( ) (a., b. ) 11) ( 108 ) 25. ( ) ( ) ( ) (a., b. ) ( ) ( ) ( ) ( ) 12) D-dimer (a., b. ) 26. (a., b. ) (a., b., c. ) ( ) ( ) ( ) ( 108 ) FISH (a., b. 7
8 ) ( 108 BCR/ABL 1 ) 30. α ( ) ( ), ( ) ( ) ( ) (a., b. ) (a., b. ) 31. ( ) ( ) Wilson (a., b. ) (a., b. ) Leigh ( ) ( ) (a., b. ) ( ) Gaucher ( ) (a., b. ) (a., b. ) Machado-Joseph (a., b., c., d. ) MJD CAG ( ) 7) Duchenne Becker ( ) ( ) (a. Duchenne, b. Becker) (a. Duchenne, b. Becker) 32. ( ) ( 108 ) CT MRI (a., b. ) ( ) ( ) ( ), ( ) ( 108 ) 35., ( ), ( ) ( ) (a., b., c. ) (a., b., c. ) (a., b. ) (a., b. ) 17) (a., b. ) 8
9 PCR PCR (a., b., c. ) (a., b. ), (a., b. ) ( ) (a., b. ) (a., b. ) (a., b. ) (a., b. ) (a., b., c. ) PET/CT (a., b., c. ) (a., b. ) 38. ( ) 16) ( ) (a., b., c., d. ) (a., b. ) (a. CT, b. MRI, c. SPECT, d. PET/CT) 18) ( ) (a., b. ) (a., b., c. ) ( ) ( ) 19) ( ) (a., b., c., d. β, e. ) ( ) (a., b., c., d., e. ) (a., b., c., d., e. ) ( ) (a. β, b. β, c. α, d. α ) ( ) ( ) 5) ( ) (a., b. ) ( ) 20) ( ) 45. 9
10 (a., b. ) ( ) (a., b. ) CT MRI (a., b. ) (a., b., c. ) 15) (a., b. ) ( ) ( ) (a., b. ) ( ) (a., b. ) (a., b., c. ) Jo-1 ( ) ( ) % DNA (a., b. Sjögren, c., d. SLE, e. ) ( ) ( ) (a., b., c. ) (a., b. ) (a., b. Sjögren, c., d. SLE, e. ) I ( ) ( ) 51. ( ) Staphylococcus Streptococcus (a., b. ) β (a., b., c. ) ( ) ( ) 52. ( ) ( ), ( ),, ( ) ( ) ( ) ( ) ( ) (a., b. ) (a., b. ) 10
11 ( ) (a., b. ) ( ) (a., b. ) (a., b. ) ( ) ( ) TGF-β ( ) ( ) (a., b., c. ) (a., b. ) ( ) 8) ( ) (a., b., c. ) ( ) ( ) 55. (a., b. ) B B ( ) ( ) ( ) ( ) ( ) ( ) 1 2 ( ) ( ) ( ) (a., b. ) 45 (a., b. ) ( ) (a., b. ) ( ) ( ) 21) (a., b. ) ( ) LDH ( ) ( ) (a., b. ) 56. ( ) (a., b. ) ( ) 57. ( ) ( ) (a., b. ) ( ) 11
12 58. HTLV-1 ( ) HTLV-1 (a. B, b. T ) (a. CD4, b. CD8, c. CD20) (a., b. ) HTLV-1 (a., b. ) HTLV-1 RANK (a. K, b. K, c. Ca, d. Ca ) ( ) 22) 59. ( )
13 3.2 B ( ) ( ) 2. ( ) (a., b. ) (a., b., c. ) (a., b. ) (a %, b %, c. 0.5 %, d. 1 %) (a., b. ) (a., b., c. ) (a., b., c. ) (a., b. ) ( ) Hz (a. α, b. β, c. γ, d. δ, e. λ, f. θ) (a., b. ) (a., b. ) (a., b. ) REM ( ) (a., b. ) (a., b. ) 11. ( ) (a., b., c. ) 10 ( ) 7)
14 (a., b. ) (a., b. ) (a., b. ) 13. AIDS AIDS ( ) ( ) ( ) ( ) ( ) ( ) ( ) AIDS 5) ( ) AIDS PIVKA-II ( ) ( ) ( ) ( ) ( ) (a., b., c., d. ) (a., b., c., d. ) (a. A, b. B, c. C, d. D, e. E., f. K) ( ) PIVKA-II (a., b. ) ( ) PIVKA-II (a., b. ) ( ) ( ) 4) 22. ( ) ( ) ( ) 1 (a., b., c., d., e., f. ) ( ) ( ) 2 (a., b., c., d., e., f. ) ( ) ( ) 3 (a., b., c., d., e., f. ) ( ) ( ) 9) ( ) 4) (a. 1, b. 2, c. 3, d. ) 14
15 23. ( ) HE (a., b. ) (a., b. ) (a., b. ) ( ) (a., b., c., d. ) (a., b., c., d. ) (a., b., c., d., e. ) ( ) ( ), ( ) 26. (a., b. ) (a., b., c. ) ( ) ( ) (a., b., c. ) (a., b., c., d. ) (a., b., c. ) ( ) ( ) (a., b. ) ( ) (a., b. ) ( ) (a., b. ) 2)
16 (a., b., c. ) (a., b., c., d. ) (a., b. ) (a., ) (a., b. ) 6) (a., b. ) (a., b., c., d. ) ( ) 23) 36. (a., b. ) 20) (a., b. ) (a., b. ) (a., b., c. ) Na + -K + ATPase (a., b., c. ) Na + (a., b. ) (a., b. ) ( ) Na + (a., b., c. ) (a., b. ) (a., b. ) ( ) (a., b. ) (a., b. ) (a., b. ) ( ) ( ) (a., b. ) ( ) (a., b. ) ( ) ( ) ( ) ( ) 24) ( ) ( ) ( ) ( ) ( ) 42. ( ) ( ) body mass index (BMI) 16
17 BMI ( ) ( ) BMI (a., b., c., d. ) BMI BMI ( ) 7) Nelson Textbook of Pediatrics 25) 3 BMI ( ) (97 ) (a. 2, b. 6, c. 10) BMI 20) (a., b., c. ) (a., b. ) (a., b., c. ) ( 108 ) 45. postpartum depression (a., b. ) (a., b. ) (a., b. ) ( 108 ) (a., b., c. ) (Systemic Lupus Erythemathosus; SLE) 70 % ( ) ( ) ( ) 2) (a. I, b. II, c. III, d. IV ) SLE SLE (a., b. ) ( 108 SLE ( ) SLE ) 49. ( ) (a , b , c ) (a , b , c ) 26) (a., b., c. 17
18 ), ( ) ( ) (a., b. ) ( ) ( ) ( ) ( ) (a., b., c. ) ( ) ( ), ( ),, ( ) ( ) ( ) 26) HMG-CoA ( ) 10) ( 108 B-54 ) ( ) ( ) (a., b. ) (a., b. ) B 1 ( ) ( ) 8) B 1 ( ) ( ) B ( ), ( ), ( ) ( ) 7) ( ) 7) ( ) ( ) ( ) (a., b. ) 60. (Motor nerve Conduction Velocity; MCV) ( ) (Compound Muscle Action Potential; CMAP) (a. E, b. F, c. N, d. M) ( ) latency ( ) ( ) ( ) ( ) ( ) ( ) CMAP ms ( ) (a., b., c., d. ) CMAP (a., b., c. ) (a., b., c. ) (a., b. ) 18
19 (a., b. ) F ( ) 27) ( 108 ) 61. Guillain Barré ( ) (a., b., c. ) 17) ( ) ( ) ( )
20 3.3 C ( ) 6 (a., b., c. ) (a., b., c. ) ( ) ( ), ( ), ( ) 3 8) 5. (a., b., c. ) (a., b., c. ) ( ) 14) (a., b. ) (a., b., c. ) (a., b., c. ) ( ) (a., b., c. ) 23) 8. ROC 28) (a., b., c. ROC ) ( 108 ) 9. ( ) ( ) (a., b., c. ) 10. ( ) ( ) ( ) 26) ( 108 ) 11. ( ) ( ), ( ) 20
21 ( ) ( ) 17) (a., b., c. ) (a., b. ) ( 108 ) ( 108 ) ( 108 )
22
23 3.4 D ( ) (a., b. ) (a. 800, b. 80, c. 8) (a., b. ) (a., b. ) ( ) ( ) 13) ( ) (a , b , c ) mmhg 7) 5. ( ) ( ) ( ) (a. S1, b. S4) (a., b. ) S1 S4 (a. S1, b. S4) 4) 6. seizure generalised seizure ( ) focal seizure ( ) ( ) primary generalised seizure ( ) secondary generalised seizure ( ) ( ) (a., b., c. ) (a., b., c., d., e. ) (a., b. ) (a., b., c. L, d. T ) ( ) ( ) Na + ( ) (a., b. ) Na + T (a., b. GABA, c. ) (a., b. ) ( ) ( ) ( ) 10) 7. Wiskott-Aldrich (a., b. X, c. Y ) WAS deletion (a., b., c. ) ( ), ( ) WAS ( ) 25) ( 108 ) 8. Creutzfeldt-Jakob (CJD) ( ) ( ) ( ) 134 C 1 23
24 (SDS) 1) SDS (a. Polymerase Chain Reaction (PCR), b., c. ) 29) ( ) ( ) (a., b., c. ) ( ) ( ) ( ) (a., b. ) 5) syndrome ( ) sequence ( ) ( ) Potter sequence ( ) (a., b. ) ( ) 5, 25) Potter sequence (a., b. ) ( ) 16. ( ) ( ) 22) (a., b., c. ) ( ), ( ), ( ) (International Prognostic Scoring System; IPSS) 22) IPSS (a., b., c. ) ( 108 ) 17. (a., b. ) (a., b. ACTH, c. ) ( ) 24
25 (a., b. ) ( ) 11-α ( ) Paragonimus westermanii,,, (a., b., c. ) (a., b. ) 30) ( 108 ) 22. (Computed Tomography; CT) (a., b. ) ( 108 ) 23. ( 108 ) 24. ( 108 ) 25. ( ) ( 108 ) Blumberg ( ) ( ) ( ) 7) 25
26 (a., b. ) (a., b. ) (a., b. ) 15) (a., b. ) ( 108 ) 28. ( ) (a., b., c., d. ) (a., b. ) (a., b. ) ( ) 8) 29. (a., b., c. ) (a., b., c. ) ( ) (a., b. ) ( ) 9) ( ) 7) ( 108 ) 30. Huntington 4p16.3 ( ) CAG (a., b., c. ) ( ) ( ) ( ) CAG (a., b., c. ) ( ) (a., b. ) (a., b. ) Charcot-Marie-Tooth (a., b., c. X, d. ) ( ) ( ) (a., b. ) (a., b , c. ) Duchenne Becker (a., b., c. ) Genomics ( ) ( ) (a. 1, b. 15, c. 30, d. 45) (a. Duchenne, b. Becker ) 16 ( ) 17) 31. (a., b., c., d. ) ( ) ( ) (a. 5-10, b , c ) % ( ) (a., b. ) ( ) (a., b. ) 31)
27 34. ( ) ( ) ( ) ( ),, ( ) ( ) ( ) ( ) 2) ( ) ( ) ( 108 ) 37. (Toxic Epidermal Necrolysis; TEN) ( ) ( ) ( ) TEN ( ) (a., b., c., d. ) ( ) (a., b., c. ) (a., b., b. T ) 2) ( ) ( ) (a., b., c. ) 15) 2) ( 108 (Staphylococcal Scalded Skin Syndrome; SSSS) a. b. ) 38. ( ) ( ) 13) ( 108 ) 27
28 44. (a., b., c., d. ) ( ) 4) ( 108 ) 45. ( ) ( ) ( ) (a., b., c. ) 17) ( 108 CRP MRI ) ( 108 ) ( 108 ) 50. ( 108 ) ( 108 ) ( 108 ) 28
29 58. KL-6 ( ) (a., b., c. ) (a., b. ) (a., b. ) ( ) ( ) ( ) ( ) KL ) ( 108 ) ( ) ( ) CCP 32) 59. ( 108 )
30 3.5 E ( ) 24 ( ) (a., b., c. ) 7) 3. (a., b., c., d. ) (a., b., c. ) (a., b. ) 7) (a., b., c., d. ) (a., b., c., d. ) ( ) (a., b., c. 17-, d. ) ( ) 20) HE (Bowman ) (Descemet ) 33) 34) (a., b., c., d. ) (a., b., c., d. ) (a., b. I, c. II ) (a., b. ) (a. I, b. II, c. III, d. IV ) ( ) (a., b. I, c. II ) ( ) (a., b. ) (a., b., c. ) 33) (a., b., c., d. ) (a., b. ) 34) 13) 33) (
31 ) (a., b. ) (a., b., c. ) (a., b., c. ) 25) (a., b., c., d. ) (a. 1-2 %, b %, c %) 20) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) 2) ( ) 14. (a., b. ) (a., b. 3-8, c. 9 ) (a., b. 3-8, c. 9 ) (a. 8-15, b , c. 26 ) (International Commission on Radiological Protection; ICRP) 100 msv 35) (a., b. 1 msv, c. 10 msv, d. 50 msv ) 15. (a., b., c. ) 36) ( 108 )
32 20. ( ) 2001 ( ), ( ), ( ) 3 36) (a., b. ) (a., b. ) (a., b. ) 15) Rome III 3 1) (a., b. ); 2) (a., b. ); 3) (a., b. ) 8) Virchow (a., b. ) ( ) ( ) May R Thurner J 22 % 37) - 7) ( 108 ) ( 108 ) (a., b. ) (a., b. ) Retinitis Pigmentosa Retinopathia Pigmentosa (a., b. ) ( ) (a., b. ) (a., b. ) 13) ( ) ( ) ( ) 38) (Electroretinogram; ERG) ( ) ( ) ( ) ( ) 13) 32
33 ( ) ( ) ( ) (a. damp, b. dtmp, c. dgmp, dcmp) ( ) (a., b., c. ) RNA (a., c., b. ) MCV ( ) ( ) 22) (a., b., c. ) ( ) WHO (a., b. ) (a. 3, b., c., d. ) ( ) (a., b., c. ) ( ) WHO ( ) 36. ( 108 c ) 37. (a., b., c. ) ( ) ( ) (a,, b. ) (a., b. ) ( ) (a., b. ) (a., b., c. ) (a., b., c. ) (a., b. ) (a., b., c., d. ) 14) 33
34 ( ) 40. (a., b., c. ) 4 ( ) 41. ( ) (a., b. ) 42. (a., b. ) (a., b. ) (a., b. ) (a., b., c., d. ) µg/dl ( ) µg/dl δ- (a., b., c. ) 39) ( ) G6PD G6PD 40) (a., b., c. ) 39) ( 108 ) 43. ( ) ( ) ( ) (a., b. ) (a., b g, c. ) ( ) ( ) ( ) ( ) ( ) ( ) (a. 5, b. 15, c. 30, d. 45) (a. 5, b. 15, c. 30, d. 45) ( ) (a., b., c. ) ( ) 9) 44. ( 108 ) 45. TNM 34
35 (a., b. TNM ) IV ( ) III ( ) 41) 46. ( 108 ) 47. ( 108 ) ( 108 ) ( 108 ) ( ) ( ) ( ) ( ) (a., b., c. ) 55. ( ) (AChE) ( ) (a., b., c. ) VX AChE P=O AChE ( ) AChE P=O ( ) (a., b., c. ) (a., b. ) (a., b. ) AChE ( ) ( ) AChE ( ) (a., b., c. ) ( ) ( ) AChE 39) 35
36 56. ( ) ( ) (a., b. ) 9) ( 108 CT ) I ( ) II ( ) ( ) III II (a. I, b. II, c. III ) 9 (a., b., c. ) I (Burn Index; BI) II ( ) III 42) ( 108 )
37 3.6 F ( 108 ) 5. ( 108 ) (a., b. ) (a., b. ) ( ) ( ) ( ) ( ) (a., b. ) 2) (a., b. ) (a., b. ) (a., b. ) (a., b. ) ( ) ( 108 ) 10. ( 108 )
38 ( ) ( ) ( ) ( ) ( ) 16) : a., b., c., d., e ( 108 ) Glasgow Coma Scale (GCS) E ( ) V ( ) M ( ) = 15 3 E ( ) V ( ) M ( ) 12) 21. ( 108 ) 22. ( ) (a., b., c. c. ) 13) ( 108 FAST ) (a. 10, b. 20, c. 30, d. 40) mm ( ) ( ) (a. α, b. β, c. α, d. β ) ( ) (a., b., c. ) NSAID ( ) 9)
39 ( 108 ) ( 108 F-27 c ) ( 108 Buerger ) ( 108 ) 39
40 3.7 G ( 17( )202) (a., b. ) (a., b. ) 43) ( 108 ) (a., b., c., d. ) ( ) (a., b., c. ) ( ) (a., b. ) (a., b., c. ) ( ) (a., b. ) (a., b., c. ) (a., b. ) ( ) ( ) 2) 8. (a. tight junction, b. adherence junction, c. desmosome, d. hemidesmosome) ( ) ( ) ( ) 2) ( 108 ) 9. (a., b. ) Na + -Ca 2+ Na + ( ) Ca 2+ 1 (a., b. ) Na + (a., b. ) 44) (a., b. ) 14) 40
41 10. K (a., b. ) K (a., b. ) (a., b. ) (a., b. ) (a., b. ) (a., b. ) (a., b. ) (a., b. ) (a., b. ) ( ) (a., b. ) ( 108 ) 11. primitive reflexes 4 ( ) ( ) ( ) ( ) ( ) 25) 12. (a., b. ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) 1 ( ) ( ) ( ) (a., b. ) 3) ( ) 10) ( ) ( ) ( ) κ δ 12)
42 ( ) ( ) 16) 25. ( ) (a., b. ) (a., b. ) (a., b. ) (a., b., c., d. ) (a., b., c., d. ) 14) (a., b. ) (a., b. ) ( ) (a., b. ) TNM ( ) (a. I, b. II, c. III, d. IV) (a., b., c. ) TNM N > 0 (a., b. ) ( 108 ) ( ) (a., b., c. ) ( ) ( ) ( ) (a., b., c., d. ) ( ) 45)
43 Clostridium difficile ( ) 1, 46) ( ) ( ) ( 108 ) 36. (a., b. ) ( 108 ) 37. Courvoisier ( ) 7) 38. ( 108 a b ) ( ) ( ) 2) 41. (a. 1, b. 5, c. 10, d. 15) ( ) (a., b. X, c. ) ( ) 7) ( 108 ) 42. ( 108 e. )
44 44. ( ) ( ) (a., b. ) ( ) (a. 5, b. 15, c. 25) mg/dl 24 ( ) ( ) (a. 2, b. 2, c. 2 ) ( ) Erythroblastosis Fetalis ( ) ( ) ( ) ( ) 25) ( 108 ) 45. ( ) 7) ( ) ( ) ) ( 108 ) 46. ( ) ( ) (a., b., c. ) 5) CT ( ) PET ( ) (a., b., c. MRI, d. X, e. ) ( ) 44
45 (Amniotic Fluid Index; AFI) (a. 3, b. 5, c. 7, d. 9) cm (a, 14, b. 16, c. 18, d. 20) cm (a., b. ) ( ) 1 2 (a. 1-2, b. 5-25, c ) bpm ( ) 32 (a. 5, b. 15, c. 25) bpm (a. 30, b. 15 2, c. 1 ) (a., c. ) (a, b., c. ) (a. 5, b., 15, c. 25) bpm (a. 5, b. 15, c. 25) bpm 15 (a. 30, b. 1, c. 2 ) (a., b., c. ) (a., b., c. ) ( ) ( ) 9) 54. (a. 0.3, b. 0.8, c. 3, d. 8) % 9) ( 108 c. )
46 3.8 H 1. ( ) 45) ( ) (a., b., c., d. ) (a., b. ) 19) asterixis ( ) wing beating ( ) 17) 14. ( 108 b )
47 ( 108 ) 27. ( 108 ) 28. ( 108 b ) (a., b. ) (a., b. ) ( a 32 )
48 ( d ) ( e ) ( 108 Libman-Sacks (Systemic Lupus Erythematosus; SLE) 48
49 3.9 I ( 108 ) (a., b., c., d. ) (a., b. ) (a., b. ) 7) 7. ( 108 ) (a., b., c., d. ) (a., b. ) (a., b., c. ) (a., b. ) (a., b., c., d. ) (a., b., c. ) (a., b. ) (a., b. ) ( 108 a. ) 11. Selective Estrogen Receptor Modulator (SERM) ( ) ( ) ( ) 10) 12. ( 108 ) 49
50 (a , b. 0.15, c. 1.5, d. 15) 15) Waterhouse-Friderichsen syndrome ( ) ( ) ( ) 5) 16. botulinum toxin ( ) ( ) (a., b. ) (a., b. ) (a., b. ) tetanospasmin ( ) (a., b. ) (a., b. ) (a., b. ) (a., b. ) 1) 17. ( ) ( ) ( ) ( ) 47) ( 108 ) 11) 18. recruitment ( ) ( ) ( ) ( 108 PQ I I II II ) ( 108 ) 23. ( ) ( ) 50
51 ( ) ( ) ( ) ( ) Blumberg (a., b. ) (a., b., c. ) 48) 24. (Anti-Neutrophil Cytoplasmic Antibody; ANCA) (a. p-anca, b. c-anca, c. q-anca) (a. p-anca, b. c-anca, c. q-anca) (a. PR3, b. MPO) (a. PR3, b. MPO) MPO ( ) (a., b., c. ) MPO MPO ( ) 26) ANCA IgG (a., b. ) 6) ( ) (a., b. ) (a., b. ) 5) ( 108 ) 25. ( 108 ) ( 108 e. ) (a. SSRI, b. SNRI, c., d. ) ( ) ( ) (a., b., c., d. ) ( ) ( ) ( ) 10)
52 32. ( ) (a., b., c. ) ( ) ( ) ( ) (a., b. ) (a., b., c., d. ) (a. TNF-α, b. TGB-β, c. IL-6, d. IFN-α) 22) (a., b., c., d. ) ( 5, p.145) ) 33. ( 108 ) 34. ( ) 9) ( 108 ) ( 108 ) ( 108 ) (a. BCG, b., c. ), (a., b., c. ), (a., b., c. ), (a., b., c. ) 1) 41. ( 108 ) ( ) 1) ph (a., b. ) (a., b. ) (a., b., c. ) (a., b., c. ) 7)
53 ( 108 IgE ) ( 108 ) ( 108 ) 50. ( 108 ) ( ) ( ) (a., b. ) (a., b., c. ) (a., b., c., d., e. ) 80 % (a. 9, b. 18, c. 9, d. 18 ) 7) C ( ) ( ) (a., b. ) (a. 50 %, b. 30 %, c. ) ( ) 25) 55. ( 108 )
54 57. ( ) ( ) (a., b., c. ) CT (a., b., c. ) ( ) ( ) CT ( ) (a., b. ) 49) ( ) ( ) ( ) ( ) (a., b. ) (a., b. ) 26) ( 108 ) 58. ( 108 ) 59. ( 108 ) (a., b., c. ) ( ) (a., b., c. ) (a., b. ) ( 108 ) 62. ( 108 ) ( 108 )
55 ( 108 ) 68. prostatic hyperplasia hypertrophy hyperplasia 9 Harrison s Principles of Internal Medicine 19th Ed. (a., b. ) ( ) ( ) (a., b. ) PSA (a., b. ) (a., b. ) 15) ( ) ( ) ( ) ( ) ( ) ( ) (a., b., c. ) 7) ( ) ( ) NSAID (a., b. ) ( ) ( ) ( ) 31) 73. ( ) ( ) ( ) 10) ( 108 )
56 ( 108 ) ( ) ( ) 51) AFP hcg ( ) ( ) AFP ( ) hcg ( ) 23) 5 80 % 50) AFP ( ) BEP ( ) ( ) ( ) ( ) 56
57 4 4.1 A 1., 2., 3., 4., T,, 5.,,,,,, 6.,,,, 7.,, ACTH Cushing,,,,,, α, 8.,,,, 11) 9.,,, 10.,,,,, 11.,,,, 12.,,,,,,, 13.,,,,,,,,, 14.,,, 15., 57
58 16.,,,,,,, 17.,,,,,,,,,,,,,,,,,, 18.,,,,,,,,, 19.,,,,,,,, MAO, 108 L- L- 20.,,,,,,,,, 21.,,,,,,,,,,, 22.,,,,,,,, 23.,,, 24.,, 25. P AO2, P ao2, A a D O2,, Sp O2,,,, 26.,,,,
59 30.,,,,,, 31., Y,,,,,,,,,,,,, X, Duchenne, Becker ,,,, 35.,,,,,,, ,,,,,,,,,, 38.,,,, SPECT,,,, SPECT, ,, β,,,, β,, TGF-β 44.,,, 47.,,,,,,, PET 50.,,,, /, 100, SLE,,,,, SLE, Scl-70, 51.,,, Rickettsia, 59
60 52.,,,,,,, ST,, 54.,,,,, ACE, β,,,,, β,, ACE, β 55., CD19, CD20,,,,,, 1, 10,,, BCR-ABL,,,,,,,, 56.,, 57.,,, 58. T /, T, CD4,,, Ca,
61 4.2 B , ,, 6., %, 10.,,, 8-13, α,,,, Rapid Eye Movement,, 11. IgA,, 12.,, 13.,,,, LMP, EB,, 17. Protein Induced by Vitamin K Absence II, K,, K, II,,, K,,,, 21., 4 22.,,,,,,,,,,,, 23.,,,,, 25.,,,, 26.,,,,,,,,,,,,, 35.,,,,,,, 36.,,,,,,, Na + -Ca 2+, 61
62 ,, 38.,,,,,,,,,,,, 41.,,, 6, ,, 24, 30,,, 18, 6 44.,, 45.,, 48.,,,, III, , 1.030,, 3-4,,, MRI,, ,, ,,,,, 59.,,,, Wernicke, B 1,,,,,,,,,,, 60., M,, CMAP,,,,,,,,,,,, α 61.,,,, 62
63 4.3 C 2.,, 4.,,, 5.,, 7.,,,, 8. 9.,, 10.,, 11.,,,,,, 63
64 4.4 D 2. RB,, 80,,,, 4., ,,, S1,, S4 6.,,,,,,,, T,,,,, GABA,, GABA,, GABA 7. X,,,, X 8.,,,, 12. IgH,, IgH, BCL2,, 15.,,,,,,, 16.,,,,,, 17., ACTH,,,, 11-, 21., , rebound tenderness,,,,, 64
65 28.,,,, 29.,,,,, 30. (HTT),,,,,, X,,,,,,,,, Duchenne Becker in frame,, 15, Duchenne, 31.,,, 5-10,,,, 34. A16, 71,,,,,, 36.,, 37., Stevens-Johnson, 10 %, 30 %,,,, T,,,, 38., VEGF 44., 45.,,, 58. II,,,,,, A, D,,, 65
66 4.5 E 2., 30, 3.,, 6.,, 21, 17-, 9.,, I,, I,,,,,,, 11.,,,, 6-10 % 13.,,, 24-48, Behçet,,,, 14.,, 3-8, 8-15, WHO,,, 22.,,,,, 24.,, 29.,,,,,,,,,,,, 33., B 12,, dtmp, dump,,, (RDW),,, 35.,,,,, 37.,,,,,,,,,, 66
67 40., 41., 42.,,,,,,, 43., 37, 42,,, 4000 g,,,,,, 30, 15,,, TNM, M > 0, M = 0 N > 0 54.,,,, 55.,,, P=S,,,,,, 2-PAM (pralidoxime),,,, 56., FSH, ,,, II,,
68 4.6 F 7.,,,, D,, 9.,,,, 14.,,,, 20. 4, 5, 6, 3, 3, 4 22., ,,, β,,, 68
69 4.7 G 3., 7., 5,, 3-4,,,,,,, 5, 3 8. desmosome,,, 9., 3,,, 10.,,,,,,,,,, 11., 7-8, 2-3, 5-6, , 4, 8, 12, 32, 8, 4, 8, 20,,,,, 18. µ,,, 24. depersonalisation, 25.,,,,, 27.,,,, M > 0, IV,, 30.,,,, 18,, 35.,, Koplik, 41. 5,, X, 44.,,, 24, 15,,, 2,, 69
70 ,,, RDW 45.,, ,, 48., CT 53.,, 5, 18,,, 5-25,, 15, 15 2,,, 15, 15, 2,,,,
71 4.8 H 1., 8., 13., Wilson , 71
72 4.9 I 6.,, 10.,,,,,,, 11.,, ,, 16.,,,,,,,,, 17. 1,,, 18., 23.,,,,,,, 24. c-anca, p-anca, PR3, MPO,,, Fc,,,, 30., SSRI,,,,, 32.,, JAK2,, dry tap,,, TGF-β,, -II BCG,,, 43.,,,, 52. JC,,,,, 9 54.,,, 30 %, 72
73 57.,,,,,,,, KL-6, SP-A, SP-D, II,, 61.,,, 68., PSA,,,,, α 1, 5α-,, 72.,,, Sjögren,,,, TNF-α, IL Toll-like receptor,, 80.,,,,,,,,, 73
74 1),., 12. : ; )., 2. : ; ),., 7. : ; )., 3. : ; ) Kumar V, Abbas AK, Aster JC. Robbins and Cotran Pathologic Basis of Disease, 9th Ed. Philadelphia: Elsevier; ) Rosai J. Rosai and Ackerman s Surgical Pathology, 10th Ed. Elsevier; ),,., 2. : ; )., 10. : ; ),., 4. : ; ) Golan DE, Tashjian AH, Armstrong EJ, et al. ed. Principles of Pharmacology, 3rd Ed. Philadelphia: Lippincott Wiliams & Wilkins; )., 11. : ; ),, TEXT, 4. : ; ),. TEXT, 3. : ; ),., 3. : MEDSi; ) Kasper DL, Fauci AS, Hauser SL, et al. ed. Harrison s Principles of Internal Medicine, 19th Ed. Mc Graw Hill Education; ),,., 6. : ; )., 2. : ; ),., 5. : ; ),,,,.. : ; )., 10. : ; ).. : MEDSi; )., 2. : ; ),., 9. : ; ),., 3. : MEDSi; ) Kliegman RM, Stanton BF, St Geme III JW, et al. ed. Nelson Textbook of Pediatrics, 20th Ed. Philadelphia: Elsevier; ),,., : ; ),.. : ; ),., 4. : ; ),,., 4. : ; ),,., 3. : ; ),,., 12. : ; ),,., 34. : ; ),., 19. : ; ) Mills SE. Histology for Pathologists, 4th Ed. Philadelphia: Lippincott Williams & Wilkins;
75 35),,.. : ; ).. : ; ) Fazel R, Froelich JB, Williams DM, et al, A Sinister Development, N Engl J Med 2007; 357: ) Yanoff M, Sassani JW. Ocular Pathology, 7th Ed. Mosby Elsevier; ).. : ; ),., 5. : ; ) UICC TNM. TNM, 7. : ; )., 4. : ; ), jp/detail2?id=50093 ( ). 44).. ( ). 45),., : ; )., 3. : ; ),. NEW. : ; ),,., 13. : ; ),. CT, 3. : MEDSi; )., : ; ),., 3. : ;
Microsoft Word - 平成24年度医学部卒業試験問題-2.docx
24 2012.10.25 13:00 15 00 5 2 10 20 60 80 110 10 1 6 7 /kg 1 12 20 30:2 AED 3 1 2 119 2 2 2 X X SpO 90% 60mmHg Primary Survey FAST CT 90% 100mmHg FAST 1 2L FAST(Focused assessment with sonography for trauma)
3 6 6 8 5 5 0 4 3 4 4 0,000 3 ID ID ID 4 7 9 :5 4 5 60-8048 NACOS TEL: 075-45-366 FAX: 075-45-366 E-mail: [email protected] 3. Power Point PC 0 5. Power Point PC 7 3 3. 3 5 PC PC PC Windows Power Point USB
日本呼吸器学会雑誌第48巻第6号
Fig.1 Cutaneousfindingsandpathologicalfindingsofatransbronchiallungbiopsy(TBLB)andlichenifiedeczemaoftherightforearm.Thepatienthadlichenifiedeczemaonhisextremitiesandbodytrunk (1a:rightforearm,1b:leftthigh).Therewasinfiltrationoftheinflammatorylymphocytes,edemaandabrasioninthetype2alveolarepithelium
国試過去問集.PDF
I 89 16 3 130 ab c AMPcAMP a 1 --- b c --- 2 --- --- 3 --- --- 4 --- --- 5 --- --- camp camp Ca 2+ β1 camp A camp camp A β1 p.156 β p.146 b. p.157 p135 (ANP) p157 c PDE-III p.157 p.157, 183 PDE C Ca PDE-III
A(6, 13) B(1, 1) 65 y C 2 A(2, 1) B( 3, 2) C 66 x + 2y 1 = 0 2 A(1, 1) B(3, 0) P 67 3 A(3, 3) B(1, 2) C(4, 0) (1) ABC G (2) 3 A B C P 6
1 1 1.1 64 A6, 1) B1, 1) 65 C A, 1) B, ) C 66 + 1 = 0 A1, 1) B, 0) P 67 A, ) B1, ) C4, 0) 1) ABC G ) A B C P 64 A 1, 1) B, ) AB AB = 1) + 1) A 1, 1) 1 B, ) 1 65 66 65 C0, k) 66 1 p, p) 1 1 A B AB A 67
第86回日本感染症学会総会学術集会後抄録（I）
κ κ κ κ κ κ μ μ β β β γ α α β β γ α β α α α γ α β β γ μ β β μ μ α ββ β β β β β β β β β β β β β β β β β β γ β μ μ μ μμ μ μ μ μ β β μ μ μ μ μ μ μ μ μ μ μ μ μ μ β
5 CSF 6 CSF 7 CSF CSF CDV CDV GFAP CSF Pandy test NSE MBP LDH mu/ml 0-5 /µl AST mu/ml CK mu/ml <25 mg/dl<45 mg/dl GLU
CT MRI CSFCSF CSF CSF CSF CSF CSF (cisternal puncture) CSF 20-23G 90 (20-23G) : CSF
…GŒÆ›u››‘KŒâ‚è_cs1.indd
1 1-1 4 1-2 a. b. c. d. e. 1-3 A. 4 B. 3 1-4 a. b. c. d. e. 1-5 1-6 4 1-7 a. b. c. d. e. 1-8 a. b. c. d. e. 1-9 1-10 A. 2 B. C. 1-11 a. / 2 b. / c. / d. / e. / 1-12 a. T b. c. M d. e. 1-13 1-14 1-15 16
051
Aug. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 4 389( 15 ) 1. MDS collagenase 2. 1 3. 4. / 390( 16 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 4 Aug. 4 4 2004 10 2 1 NTT Aug. THE JAPANESE JOURNAL OF ANTIBIOTICS
1) a) b) CRP c) d) e) a,b b,c c,d d,e a,e b,d 2) CKD a) ACE ARB b) 2mg/dL ACE ARB c) 2mg/dL d) e) ACE ARB a,b b,c c,d d,e a,e b,d 3) a) 130/85mmHg b)
2010.1.13 1) 4) 2 18 1) 1 2 3 4 2) 1 2 85 3 3) 1 metabolizer 2 metabolizer 3 metabolizer 4 metabolizer 4) CYP 1 2 metabolizer 3 metabolizer 4 5 6 4 7 2 5 (PPI) 1 2 PPI 2 3 2 3 3 3 3 PPI 3 1 ph 4 5 1) 5)
Microsoft Word - 三重大学版PBLマニュアル.doc
Problem-based Learning PBL * 1 * 2 * 1 Problem-based Learning Project-based Learning * 2 1 15 2 reflection self-directed learning (PBL-tutorial) (Task-based Learning, Project-based Learning) 11 3 4 (Theoretical
ｎｓｇ０２－１３／ｋｙ０４５０５９３０１６０００３３２１０
φ φ φ φ κ κ α α μ μ α α μ χ et al Neurosci. Res. Trpv J Physiol μ μ α α α β in vivo β β β β β β β β in vitro β γ μ δ μδ δ δ α θ α θ α In Biomechanics at Micro- and Nanoscale Levels, Volume I W W v W
_0212_68<5A66><4EBA><79D1>_<6821><4E86><FF08><30C8><30F3><30DC><306A><3057><FF09>.pdf
37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate
37, 9-14, 2017 : 36 2015 8 6 cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin 20 1983 2016 3 CD 7 Clostridium difficile CD CD associated diarrhea : CDAD CD 1,2 PPI 3 1 36 33 2015 8 6 5 5
研修コーナー
l l l l l l l l l l l α α β l µ l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
取扱説明書 ［F-12C］
F-12C 11.7 1 2 3 4 5 6 7 8 9 10 11 12 13 14 a bc b c d d a 15 a b cd e a b c d e 16 17 18 de a b 19 c d 20 a b a b c a d e k l m e b c d f g h i j p q r c d e f g h i j n o s 21 k l m n o p q r s a X
REM Rapid Eye Movement REM Zzz Non-REM
Sleep and sleep-related disorders in the elderly 20051027 REM Rapid Eye Movement REM Zzz Non-REM 90 180 270 360 90 How old is the elderly in sleep? 40 In: Primer of Polysomnography Circadian rhythm 24
さくらの個別指導 ( さくら教育研究所 ) A 2 2 Q ABC 2 1 BC AB, AC AB, BC AC 1 B BC AB = QR PQ = 1 2 AC AB = PR 3 PQ = 2 BC AC = QR PR = 1
... 0 60 Q,, = QR PQ = = PR PQ = = QR PR = P 0 0 R 5 6 θ r xy r y y r, x r, y x θ x θ θ (sine) (cosine) (tangent) sin θ, cos θ, tan θ. θ sin θ = = 5 cos θ = = 4 5 tan θ = = 4 θ 5 4 sin θ = y r cos θ =
BUN, CRP K mg/ cm, 49.6 kg, BMI /72 mmhg, 92/ Hb 6.7 g/dl PT-INR CT 1 MRI 2a, b T1 T2 T1 MRI
20 2 2015 1 2 3 85 K CT Abstract A case of renal subcapsular hematoma resulting from trigger point injection under excessive effect of anticoagulant YAMANE Tateki, UMEDA Akira and SHIMAO Hitoshi An 85-year-old
第１４〜１５回 Ｔ細胞を介する免疫系.pptx
MBL CD8 CD4 8.1 8.2 5.20 8.3 8.4 8.5 8.6 8.7 8.8 8.9 8.10 8.18 B7 CD28 CD28 B7 CD28 8.13 2.22 NK Toll(TLR) LBP! LPS dsrna ssrna TLR1/2/6! TLR4 TLR5 TLR3 TLR7/9 CD14! JNK/p38! MyD88! IRAK! TRAF! NFκB! TNF-α
マニュアル第４版表紙PDF
5 2004 4 1 5 2004 1968 1993 1994 1996 1998 2001 2004 3 I 1 1 2 2 3 12 4 24 5 48 6 59 7 65 8. 68 9 72 10 76 11 80 12 82 13 84 14 88 15 98 16. 106 17. (AIDS) 108 18 113 19 117 20 119 21 TPN 122 22 125 23.
44 4 I (1) ( ) (10 15 ) ( 17 ) ( 3 1 ) (2)
(1) I 44 II 45 III 47 IV 52 44 4 I (1) ( ) 1945 8 9 (10 15 ) ( 17 ) ( 3 1 ) (2) 45 II 1 (3) 511 ( 451 1 ) ( ) 365 1 2 512 1 2 365 1 2 363 2 ( ) 3 ( ) ( 451 2 ( 314 1 ) ( 339 1 4 ) 337 2 3 ) 363 (4) 46
i ii i iii iv 1 3 3 10 14 17 17 18 22 23 28 29 31 36 37 39 40 43 48 59 70 75 75 77 90 95 102 107 109 110 118 125 128 130 132 134 48 43 43 51 52 61 61 64 62 124 70 58 3 10 17 29 78 82 85 102 95 109 iii
S I. dy fx x fx y fx + C 3 C dy fx 4 x, y dy v C xt y C v e kt k > xt yt gt [ v dt dt v e kt xt v e kt + C k x v + C C k xt v k 3 r r + dr e kt S dt d
S I.. http://ayapin.film.s.dendai.ac.jp/~matuda /TeX/lecture.html PDF PS.................................... 3.3.................... 9.4................5.............. 3 5. Laplace................. 5....
日本呼吸器学会雑誌第44巻第10号
β Table1 Laboratoryfindingsonthefirstvisit Hematology WBC Neut. Lyn. Mon. Eos. Bas. RBC Hb Ht Plate 5,650 /μl 79.2 % 14.9 % 3.9 % 1.8 % 0.2 % 418 10 4 /μl 12.5g/dl 38.4 % 21.2 10 4 /μl Serology CRP IgG
Gauss Gauss ɛ 0 E ds = Q (1) xy σ (x, y, z) (2) a ρ(x, y, z) = x 2 + y 2 (r, θ, φ) (1) xy A Gauss ɛ 0 E ds = ɛ 0 EA Q = ρa ɛ 0 EA = ρea E = (ρ/ɛ 0 )e
7 -a 7 -a February 4, 2007 1. 2. 3. 4. 1. 2. 3. 1 Gauss Gauss ɛ 0 E ds = Q (1) xy σ (x, y, z) (2) a ρ(x, y, z) = x 2 + y 2 (r, θ, φ) (1) xy A Gauss ɛ 0 E ds = ɛ 0 EA Q = ρa ɛ 0 EA = ρea E = (ρ/ɛ 0 )e z
64 3 g=9.85 m/s 2 g=9.791 m/s 2 36, km ( ) 1 () 2 () m/s : : a) b) kg/m kg/m k
63 3 Section 3.1 g 3.1 3.1: : 64 3 g=9.85 m/s 2 g=9.791 m/s 2 36, km ( ) 1 () 2 () 3 9.8 m/s 2 3.2 3.2: : a) b) 5 15 4 1 1. 1 3 14. 1 3 kg/m 3 2 3.3 1 3 5.8 1 3 kg/m 3 3 2.65 1 3 kg/m 3 4 6 m 3.1. 65 5
2 W.T T.S. 70 2 1 238 WBC7400/µl, RBC 386 10 4 /µl, Hb 11.6 g/dl, Ht 36.2%, PLT 25 10 4 /µl AST 19 IU/l, ALT 11 IU/l, LDH 182 IU/l, BUN 15 mg/dl, Cr 0.54 mg/dl, CRP6.83 mg/dl, RF 353.9IU/ml, CCP 28.0IU/ml
/12/28 UP 3+, TP 4.2g/dl, Alb 1.9g/dl PSL 50mg/day 1/17 PSL 45mg/day PSL 2006/4/4 PSL 30mg/day mpsl mpsl1000mg 3 2 5/ :90 / :114/64 mmhg
17 2005/12/28 UP 3+, TP 4.2g/dl, Alb 1.9g/dl PSL 50mg/day 1/17 PSL 45mg/day PSL 2006/4/4 PSL 30mg/day mpsl mpsl1000mg 32 5/8 36.1 :90 /:114/64 mmhg 166.2 cm64.3 kg 3.9 g/dl 1.6 g/dl 382 mg/dl 408 mg/dl
顔面神経麻痺を来したMPO―ANCA 陽性の中耳炎２症例
11367 : MPOANCA MPO ANCA MPOANCA 134EU MPO ANCA 67EU MPOANCA ANCA : MPOANCAANCA antineutrophil cytoplasmic antibody ; ANCA Davies IgG ANCA PR3proteinase3ANCA MPOmyeloperoxidaseANCA Wegener PR3ANCA MPO
19 8 1970 20 10 4 1
19 8 1970 20 10 4 1 IgE 1960 % 1970 20%, 1990 40% 1998 70% 20 IgE 21 90% IgE IgE (%) 70 60 50 40 30 20 10 0 1970 1975 1980 1985 1990 1995 2000 2005 1. 2005 10 2 30 IgE 2. 3 1. B IgE T IgE IgE IgE 2 T IgE
untitled
28 20 1 31 4 2 25 1 IgG IgA IgM IgE IgM 2 60 80 70 60 60 40 20 80 35 45 kg 150cc 100 120cc 100cc 30 40cc 7,000g 500cc 120cc 120 5=600cc 600g 30 2,100cc 1,000cc 3 4 14 5 6 7 8 9 10 11 12 SIDS SIDS SIDS
72 20 Ope / class Alb g/ cm 47.9kg : /min 112/60m
72 20Ope 68 69 2006 4 50 20 / 52 2006 4 1 2006 4 4 24 class 699.4 5 2 5 23 6 6 15 6 19 6 16 Alb2.03+ 7.5g/ 6 21 153.5cm 47.9kg : 36.7 89/min112/60mmHg (-) (-)S1 S2 S3(-) S4(-) - - 6 15 (+) TP4.9g/dl Alb2.0g/
Mast Cell Tumor : MCT c-kit MCT F F MCT C c-kit DNA Canine DNA Ver DNA c-kit C c 1275 A G F c.2355 G A DNA F C F C c-kit MCT c-kit DNA MCT Kiel T B kg cm T T Stage a UW25 P MDR1 B L T B L Leptospira L
Atlas_j060419
Hill s Atlas of Veterinary Clinical Anatomy 1 29 30 2 3 4 5 31 32 33 34 35 36 37 6 7 8 9 10 11 12 13 38 39 40 41 14 15 16 17 18 19 20 21 22 23 24 25 26 27 42 43 44 45 46 47 48 49 50 51 52 53 54 55 28 81
近畿中国四国農業研究センター研究報告 第７号
230 C B A D E 50m 558 0 1km (mg L 1 ) T N NO 2 3 N NH 4 N 2.0 0 (a) 2001 1.5 6 20 21 5 1.0 0.5 0.0 2.0 1.5 1.0 0.5 0.0 14:00 17:00 (b) 2001 7 3 4 20:00 23:00 2:00 (h) 5:00 8:00 11:00 10 0 5 10 15
50mg 75mg (1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH
3240 14 8 8 50mg 75mg 13 6 25 1-(1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH O N O C 56 H 70 N 9 NaO 23 S 1292.26 5-[(1S,2S)-2-
cm H.11.3 P.13 2 3-106-
H11.3 H.11.3 P.4-105- cm H.11.3 P.13 2 3-106- 2 H.11.3 P.47 H.11.3 P.27 i vl1 vl2-107- 3 h vl l1 l2 1 2 0 ii H.11.3 P.49 2 iii i 2 vl1 vl2-108- H.11.3 P.50 ii 2 H.11.3 P.52 cm -109- H.11.3 P.44 S S H.11.3
(1.2) T D = 0 T = D = 30 kn 1.2 (1.4) 2F W = 0 F = W/2 = 300 kn/2 = 150 kn 1.3 (1.9) R = W 1 + W 2 = = 1100 N. (1.9) W 2 b W 1 a = 0
1 1 1.1 1.) T D = T = D = kn 1. 1.4) F W = F = W/ = kn/ = 15 kn 1. 1.9) R = W 1 + W = 6 + 5 = 11 N. 1.9) W b W 1 a = a = W /W 1 )b = 5/6) = 5 cm 1.4 AB AC P 1, P x, y x, y y x 1.4.) P sin 6 + P 1 sin 45
E3200 BV FOLFOX4 FOLFOX4 PFS % 0.42, 0.65 p< log-rank % FOLFOX4 8.6% FOLFOX % FOLFOX4 259/ % FOL
E3200 BV FOLFOX4 FOLFOX4 PFS 4.5 7.5 0.518 95% 0.42, 0.65 p
( )
18 10 01 ( ) 1 2018 4 1.1 2018............................... 4 1.2 2018......................... 5 2 2017 7 2.1 2017............................... 7 2.2 2017......................... 8 3 2016 9 3.1 2016...............................
4. ϵ(ν, T ) = c 4 u(ν, T ) ϵ(ν, T ) T ν π4 Planck dx = 0 e x 1 15 U(T ) x 3 U(T ) = σt 4 Stefan-Boltzmann σ 2π5 k 4 15c 2 h 3 = W m 2 K 4 5.
A 1. Boltzmann Planck u(ν, T )dν = 8πh ν 3 c 3 kt 1 dν h 6.63 10 34 J s Planck k 1.38 10 23 J K 1 Boltzmann u(ν, T ) T ν e hν c = 3 10 8 m s 1 2. Planck λ = c/ν Rayleigh-Jeans u(ν, T )dν = 8πν2 kt dν c
Note.tex 2008/09/19( )
1 20 9 19 2 1 5 1.1........................ 5 1.2............................. 8 2 9 2.1............................. 9 2.2.............................. 10 3 13 3.1.............................. 13 3.2..................................
1. 2 P 2 (x, y) 2 x y (0, 0) R 2 = {(x, y) x, y R} x, y R P = (x, y) O = (0, 0) OP ( ) OP x x, y y ( ) x v = y ( ) x 2 1 v = P = (x, y) y ( x y ) 2 (x
. P (, (0, 0 R {(,, R}, R P (, O (0, 0 OP OP, v v P (, ( (, (, { R, R} v (, (, (,, z 3 w z R 3,, z R z n R n.,..., n R n n w, t w ( z z Ke Words:. A P 3 0 B P 0 a. A P b B P 3. A π/90 B a + b c π/ 3. +
医系の統計入門第 2 版 サンプルページ この本の定価 判型などは, 以下の URL からご覧いただけます. このサンプルページの内容は, 第 2 版 1 刷発行時のものです.
医系の統計入門第 2 版 サンプルページ この本の定価 判型などは, 以下の URL からご覧いただけます. http://www.morikita.co.jp/books/mid/009192 このサンプルページの内容は, 第 2 版 1 刷発行時のものです. i 2 t 1. 2. 3 2 3. 6 4. 7 5. n 2 ν 6. 2 7. 2003 ii 2 2013 10 iii 1987
006 11 8 0 3 1 5 1.1..................... 5 1......................... 6 1.3.................... 6 1.4.................. 8 1.5................... 8 1.6................... 10 1.6.1......................
第十四改正日本薬局方第二追補
461 3 3 3 5 5 6 6 10 18 19 79 81 101 113 127 133 139 145 147 152 153 156 158 165 3 19 20 21 22 22 23 24 25 26 26 27 28 29 29 30 31 dl 32 dl 33 34 34 36 36 37 38 38 38 39 40 42 42 42 43 44 45 46 46 47 48
4.4 R............................................. 13 4.5 q.............................................. 13 4.6 s....................................
2014.04.12 2014.12.12 1 3 2 4 2.1............................................ 4 2.2 Einthoven triangle........................................ 4 2.3............................................ 4 2.4.............................................
1 2 2 ANCA pouci immune IgG C3 ANCA 68 '01 '02 7 UN 14mg/dl, Cr 0.7 mg/dl, -, - ' UN 45mg/dl, Cr 2.4 mg/dl, Ht 29.5%, 4+, cm 61
1 2 2 ANCApouci immune IgG C3 ANCA 68 '01 '02 7 UN 14mg/dl, Cr 0.7 mg/dl, -, - '03 2 3 31 UN 45mg/dl, Cr 2.4 mg/dl, Ht 29.5%, 4+, 3+ 4 14 156.0 cm 61.5 kg 36.9 158/92 mmhg 90 1. ANCA 2. 3. IgG4 deposit
I II
I II I I 8 I I 5 I 5 9 I 6 6 I 7 7 I 8 87 I 9 96 I 7 I 8 I 9 I 7 I 95 I 5 I 6 II 7 6 II 8 II 9 59 II 67 II 76 II II 9 II 8 II 5 8 II 6 58 II 7 6 II 8 8 I.., < b, b, c, k, m. k + m + c + c b + k + m log
(1) θ a = 5(cm) θ c = 4(cm) b = 3(cm) (2) ABC A A BC AD 10cm BC B D C 99 (1) A B 10m O AOB 37 sin 37 = cos 37 = tan 37
4. 98 () θ a = 5(cm) θ c = 4(cm) b = (cm) () D 0cm 0 60 D 99 () 0m O O 7 sin 7 = 0.60 cos 7 = 0.799 tan 7 = 0.754 () xkm km R km 00 () θ cos θ = sin θ = () θ sin θ = 4 tan θ = () 0 < x < 90 tan x = 4 sin
v v = v 1 v 2 v 3 (1) R = (R ij ) (2) R (R 1 ) ij = R ji (3) 3 R ij R ik = δ jk (4) i=1 δ ij Kronecker δ ij = { 1 (i = j) 0 (i
1. 1 1.1 1.1.1 1.1.1.1 v v = v 1 v 2 v 3 (1) R = (R ij ) (2) R (R 1 ) ij = R ji (3) R ij R ik = δ jk (4) δ ij Kronecker δ ij = { 1 (i = j) 0 (i j) (5) 1 1.1. v1.1 2011/04/10 1. 1 2 v i = R ij v j (6) [
2010 年 6 月 25 表 身体所見 134 cm 31 kg /60 mmhg 83/ ,
24 シンポジウム Ⅲ 要旨 NPPV NPPV 緒 IPF 4 5 1 IPF 2004 2 QOL 179 10 現 10 18 2008 10 言 状 3.4 8.3 76.2 41 37.2 13.6 3 1 症 例 呈 示症例 患者 61 主訴 既往歴 30 45 家族歴 喫煙歴 飲酒歴 職歴 現病歴 13 NSIP 15 1 HOT 15 7 2010 年 6 月 25 表 1 1998
(2009) 1... / 1 ( ) / 1 ( ) / 1 ( ), 2 ( )
212009................................................ 2............................................ 115 (2009) 1... / 1 ( )........................................... 4 2... / 1 ( )......................................